Biochemotherapy leads to lower progression‐free survival† compared with chemotherapy (high certainty).
Polychemotherapy showed no clear difference in progression‐freesurvival† compared with chemotherapy (high certainty).
Anti‐angiogenic drugs plus chemotherapy probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).
Anti‐CTLA4 monoclonal antibodies plus chemotherapy probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).
BRAF inhibitors leads to lower progression‐free survival† compared with chemotherapy (high certainty).
Anti‐PD1 monoclonal antibodies probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).
MEK inhibitors probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).